Thus, targeting Fli-1 using a pharmacological strategy could be potentially beneficial in the allo-HCT setting by (a) targeting leukemias and lymphomas that overexpress or rely on Fli-1; and (b) targeting pathogenic alloreactive T cells that utilize Fli-1 to some extent for differentiation, survival, or cellular functions. Here, FLI1 is linked to lymphoma.